Elutia Inc. Reports 5.5% Sales Increase but Wider Net Loss in Q1 2026

Elutia Inc. reported its financial results for the first quarter of 2026, revealing a net sales increase of 5.5% to $3.1 million, compared to $2.9 million in the same period last year. The growth was primarily driven by a significant rise in sales from the Cardiovascular segment, which saw a 214.4% increase to $1.0 million, while sales in the Women’s Health segment decreased by 20.4% to $2.1 million. The company attributed the decline in Women’s Health sales to the termination of its distribution agreement with Tiger, which had previously contributed $0.9 million in sales during the first quarter of 2025.

Elutia's gross profit for the quarter was $1.8 million, reflecting a gross margin of 57.9%, up from 46.8% in the prior year. This improvement was attributed to a decrease in the cost of goods sold, which fell by 16.4% to $1.3 million. The company reported total operating expenses of $8.2 million, slightly down from $8.3 million in the previous year, with notable increases in research and development expenses, which rose by 126.5% to $2.0 million as the company focused on advancing its NXT-41 and NXT-41x product lines.

Despite the increase in sales and gross profit, Elutia reported a net loss of $7.5 million for the quarter, compared to a net loss of $3.9 million in the same period last year. The loss from continuing operations was $7.9 million, significantly higher than the $1.9 million loss reported in the first quarter of 2025. The company also experienced a loss of $1.7 million on the revaluation of its warrant liability, which contributed to the overall increase in net loss.

In terms of operational developments, Elutia has undergone significant strategic changes, including the divestiture of its CIED Business in October 2025 and the Orthobiologics Business in November 2023. The company received approximately $88 million from the sale of the CIED Business and $14.6 million from the Orthobiologics sale, with potential additional earn-out payments. These divestitures have allowed Elutia to focus on its core product offerings in the Women’s Health and Cardiovascular segments, which are expected to drive future growth.

Looking ahead, Elutia anticipates continued operating losses and negative cash flows as it invests in the development and commercialization of its new product lines. The company had cash and cash equivalents of approximately $28.5 million as of March 31, 2026, which it believes will be sufficient to fund its operations for at least the next year. However, Elutia acknowledges the uncertainty surrounding its future profitability and may seek additional capital through equity or debt financing to support its ongoing operations and product development initiatives.